Navigation Links
PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by

NEW YORK, July 23, 2014 /PRNewswire/ -- PositiveID Corp. (OTCQB: PSID), based in Delray Beach, Fla., is an emerging player in the bio-threat detection market, that develops molecular diagnostic systems for bio-threat detection and rapid medical testing. The Company's proprietary airborne pathogen detection system called M-BAND (Microfluidic Bio-agent Autonomous Networked Detector), was developed under contract with the U.S. Department of Homeland Security ("DHS") Science & Technology directorate, and $30 million of contract funding.

The Company is nearing initial revenue recognition and the recent first ever issuance of revenue guidance by management builds confidence that progress is being made and that we have visibility to deployment of the Company's products. The Company issued revenue guidance through the end of 2015 of $4-10 million (combined between 2014 and 2015), $3.5 million of which is already in backlog.  

An analyst report by Small Cap IR detailing the current situation, summary and investment thesis, an overview of the company background, product review, current customers, recent developments, risk factors and analyst recommendation can be viewed in its entirety by using the link below. There is no cost required to view this report:

copy and paste to browser may be required.


This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   


Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Anderegg, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.

A full disclaimer can be found by viewing the full analyst report.

If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at For any urgent concerns or inquiries please contact us at


Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
2. CVS Caremark Provides Long-Term Enterprise Growth Strategy and 2014 Guidance at Annual Analyst Day
3. CVS Caremark To Host 2013 Analyst Day For The Investment Community
4. MEI Pharma To Host Analyst And Investor Day
5. Cyberonics To Webcast Presentations From Companys Investor And Analyst Meeting
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. Frost & Sullivan Hosts Analyst Briefing: An Outlook of Azerbaijan and Iran Healthcare Markets
8. The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
9. Compass Diversified Holdings to Host Investor and Analyst Event On June 12, 2013
10. Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalDatas 700 Market Analysts
11. The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy
Post Your Comments:
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA ... EPIX ) announced today that the first patient ... of EPI-506 as a treatment for metastatic castration-resistant prostate ... and Canada.  --> the ... In the Phase 1/2 clinical trial, ESSA intends ...
(Date:11/24/2015)... -- Sectra (STO: SECT B) announces that ... multi-year agreement to deploy Breast Imaging PACS in ... the Breast Center a future-proof platform capable of expanding with ... announces that Breast Center of Acadiana has entered ... PACS in its two freestanding imaging centers. This investment will ...
(Date:11/24/2015)... 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ASDS ... of Directors has declared a special 1 percent stock dividend ... payable December 14, 2015, to shareholders of record December 7, ... additional shares of common stock. --> ... a strong endorsement of our confidence in Ascendant,s growth strategy ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to ... for dental implants at her Mississauga, ON practice. Dr. Williams has been ... placement of dental implants. , Missing teeth can lead to a variety of ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the leading ... health and global clinical supply services, today announced that Dr. Christine Milligan, Global ... Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, Republic ...
(Date:11/24/2015)... MA (PRWEB) , ... November 24, 2015 , ... ... announced that the organization will waive paid entry and parking fees at several ... Hingham, and Monument Mountain in Great Barrington in support of REI’s Black Friday ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... the United States to support their local poison centers through donations on Tuesday, ... #GivingTuesday: calls it “a day that inspires people to collaborate in improving ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Cold Shoulder , LLC launched their ... last week and hit their goal of $20,000 in under 10 hours. ... to bring the new PRO Weight Loss Vest to the market. , The PRO Vest ...
Breaking Medicine News(10 mins):